Neurological Disorder Drugs Global Market Report 2024

Global Neurological Disorder Drugs Market Report 2024

Neurological Disorder Drugs Global Market Report 2024 – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes), By Indication (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-Users (Hospitals, Specialty Clinics, Homecare, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Name: Neurological Disorder Drugs Global Market Report 2024
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Neurological Disorder Drugs Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : 175 | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Global Neurological Disorder Drugs Market Infographic

Proud Members Of

Neurological Disorder Drugs Market Definition

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

The main types of drug classes in neurological disorders are cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors are medications that prevent the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function. Which can be used for various indications such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebrovascular disease, and others, through various routes of administration, including oral, parenteral, and others. And these can be distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and end users are hospitals, specialty clinics, home care, and others.

Neurological Disorder Drugs Market Segmentation

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Global Neurological Disorder Drugs Market Size 2023 to 2028: Graph

Neurological Disorder Drugs Market Size 2024 And Growth Rate

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $79.67 billion in 2023 to $84.60 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure.

Neurological Disorder Drugs Market Growth Forecast

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $108.05 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine.

Book your 30 minutes free consultation with our research experts

Neurological Disorder Drugs Market Driver: Rising Neurological Disorders Drive Growth In Drugs Market

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological disorder drugs market going forward. Neurological disorders refer to the conditions affecting the brain, spinal cord, and nerves caused by structural, biochemical, or electrical abnormalities, leading to various symptoms. The increase in neurological diseases is attributed to the aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs play a critical role in managing these complex conditions, offering relief from symptoms, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2021, according to a report published by the UK Parliament, a UK-based government body, the number of people waiting to begin neurology treatment increased to 140,482 in June 2021, up from 134,245 in May 2021. Therefore, the increasing prevalence of neurological disease is driving the growth of the neurological disorder drugs market.

Global Neurological Disorder Drugs Market Major Players

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Global Neurological Disorder Drugs Market Trend: Innovative Approaches In Neurological Disorder Drugs Advancing Treatment For Multiple Sclerosis

Major companies operating in the neurological disorder drugs market are focusing on developing innovative Ocrelizumab drug therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody used as a therapeutic drug in the treatment of multiple sclerosis (MS), a type of neurological disorder. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Ocrevus (Ocrelizumab), a new disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis in India. Ocrevus is the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), based on over 10 years of clinical and real-world data. It is a monoclonal antibody that targets CD20-positive B cells, which are believed to play a role in the autoimmune attack on the central nervous system in multiple sclerosis (MS). Ocrevus is used to treat both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making it the first drug approved for both forms of the disease. It is administered intravenously, typically every six months, and has shown efficacy in reducing disease activity and disability progression in clinical trials.

Neurological Disorder Drugs Market Merger And Acquisition: Pfizer's Acquisition Of Biohaven Pharmaceuticals Enhancing Global Leadership In Migraine Treatments

In October 2022, Pfizer Inc., a US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for $11.6 billion. Through this acquisition, Pfizer aims to strengthen its innovative internal medicine pipeline and global reach in migraine treatments by gaining access to Biohaven's breakthrough calcitonin gene-related peptide portfolio, including the approved NURTEC ODT and pipeline assets such as Zavegepant. Pfizer aims to deliver these innovative therapies to over 1 billion people worldwide affected by migraine. Biohaven Pharmaceutical is a US-based, clinical-stage biopharmaceutical company that offers a range of neurological and neuropsychiatric disorder drugs.

Regional Insights For The Global Neurological Disorder Drugs Market

North America was the largest region in the neurological disorder drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurological disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides neurological disorder drugs market statistics, including neurological disorder drugs industry global market size, regional shares, competitors with a neurological disorder drugs market share, detailed neurological disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. This neurological disorder drugs market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Neurological Disorder Drugs Market Report Forecast and Analysis

Report Attribute	Details
Market Size Value In 2024	$84.60 billion
Revenue Forecast In 2033	$108.05 billion
Growth Rate	CAGR of 6.3% from 2024 to 2033
Base Year For Estimation	2023
Actual Estimates/Historical Data	2018-2023
Forecast Period	2024 - 2028 - 2033
Market Representation	Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered	1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes 2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Neurological Disorder Drugs Market Characteristics

3. Neurological Disorder Drugs Market Trends And Strategies

4. Neurological Disorder Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market

4.2. Ukraine-Russia War Impact On The Market

4.3. COVID-19 Impact On The Market

5. Global Neurological Disorder Drugs Market Size and Growth

5.1. Global Neurological Disorder Drugs Market Drivers and Restraints

5.1.1. Drivers Of The Market

5.1.2. Restraints Of The Market

5.2. Global Neurological Disorder Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

5.3. Global Neurological Disorder Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neurological Disorder Drugs Market Segmentation

6.1. Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Cholinesterase Inhibitors

N-Methyl-D-Aspartate (NMDA) Receptor Antagonists

Antiepileptic

Antipsychotic And Antidepressant

Other Drugs Class

6.2. Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Epilepsy

Alzheimer’s Disease

Parkinson’s Disease

Multiple Sclerosis

Cerebrovascular Disease

Other Indications

6.3. Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Oral

Parenteral

Other Route Of Administration

6.4. Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Other Distribution Channel

6.5. Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End Users

7. Neurological Disorder Drugs Market Regional And Country Analysis

7.1. Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

7.2. Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neurological Disorder Drugs Market

8.1. Asia-Pacific Neurological Disorder Drugs Market Overview

Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.3. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.4. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neurological Disorder Drugs Market

9.1. China Neurological Disorder Drugs Market Overview

9.2. China Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.3. China Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.4. China Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neurological Disorder Drugs Market

10.1. India Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.2. India Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.3. India Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neurological Disorder Drugs Market

11.1. Japan Neurological Disorder Drugs Market Overview

11.2. Japan Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.3. Japan Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.4. Japan Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neurological Disorder Drugs Market

12.1. Australia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.2. Australia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.3. Australia Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neurological Disorder Drugs Market

13.1. Indonesia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.2. Indonesia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.3. Indonesia Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neurological Disorder Drugs Market

14.1. South Korea Neurological Disorder Drugs Market Overview

14.2. South Korea Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.3. South Korea Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.4. South Korea Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neurological Disorder Drugs Market

15.1. Western Europe Neurological Disorder Drugs Market Overview

15.2. Western Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.3. Western Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.4. Western Europe Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neurological Disorder Drugs Market

16.1. UK Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.2. UK Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.3. UK Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neurological Disorder Drugs Market

17.1. Germany Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.2. Germany Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.3. Germany Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neurological Disorder Drugs Market

18.1. France Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.2. France Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.3. France Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neurological Disorder Drugs Market

19.1. Italy Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.2. Italy Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.3. Italy Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neurological Disorder Drugs Market

20.1. Spain Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.2. Spain Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.3. Spain Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neurological Disorder Drugs Market

21.1. Eastern Europe Neurological Disorder Drugs Market Overview

21.2. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.3. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.4. Eastern Europe Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neurological Disorder Drugs Market

22.1. Russia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.2. Russia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.3. Russia Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neurological Disorder Drugs Market

23.1. North America Neurological Disorder Drugs Market Overview

23.2. North America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.3. North America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.4. North America Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neurological Disorder Drugs Market

24.1. USA Neurological Disorder Drugs Market Overview

24.2. USA Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.3. USA Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.4. USA Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neurological Disorder Drugs Market

25.1. Canada Neurological Disorder Drugs Market Overview

25.2. Canada Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.3. Canada Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.4. Canada Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neurological Disorder Drugs Market

26.1. South America Neurological Disorder Drugs Market Overview

26.2. South America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.3. South America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.4. South America Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neurological Disorder Drugs Market

27.1. Brazil Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.2. Brazil Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.3. Brazil Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neurological Disorder Drugs Market

28.1. Middle East Neurological Disorder Drugs Market Overview

28.2. Middle East Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.3. Middle East Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.4. Middle East Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neurological Disorder Drugs Market

29.1. Africa Neurological Disorder Drugs Market Overview

29.2. Africa Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.3. Africa Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.4. Africa Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neurological Disorder Drugs Market Competitive Landscape And Company Profiles

30.1. Neurological Disorder Drugs Market Competitive Landscape

30.2. Neurological Disorder Drugs Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd

30.2.1.1. Overview

30.2.1.2. Products and Services

30.2.1.3. Strategy

30.2.1.4. Financial Performance

30.2.2. Bayer AG

30.2.2.1. Overview

30.2.2.2. Products and Services

30.2.2.3. Strategy

30.2.2.4. Financial Performance

30.2.3. Sanofi S.A

30.2.3.1. Overview

30.2.3.2. Products and Services

30.2.3.3. Strategy

30.2.3.4. Financial Performance

30.2.4. AstraZeneca PLC

30.2.4.1. Overview

30.2.4.2. Products and Services

30.2.4.3. Strategy

30.2.4.4. Financial Performance

30.2.5. Abbott Laboratories

30.2.5.1. Overview

30.2.5.2. Products and Services

30.2.5.3. Strategy

30.2.5.4. Financial Performance

31. Neurological Disorder Drugs Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. GlaxoSmithKline plc

31.3. Takeda Pharmaceutical Company Limited

31.4. Eli Lilly and Company Pvt Ltd

31.5. Amgen Inc

31.6. Boehringer Ingelheim GmbH

31.7. Novo Nordisk A/S

31.8. Merck KGaA

31.9. Teva Pharmaceutical Industries Ltd

31.10. Otsuka America Pharmaceutical Inc

31.11. Biogen Inc

31.12. Bausch Health Companies Inc

31.13. Alexion Pharmaceuticals Inc.

31.14. UCB S.A.

31.15. Eisai Co Ltd

32. Global Neurological Disorder Drugs Market Competitive Benchmarking

33. Global Neurological Disorder Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market

35. Neurological Disorder Drugs Market Future Outlook and Potential Analysis

35.1 Neurological Disorder Drugs Market In 2028 - Countries Offering Most New Opportunities

35.2 Neurological Disorder Drugs Market In 2028 - Segments Offering Most New Opportunities

35.3 Neurological Disorder Drugs Market In 2028 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2018-2023, $ Billion

Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Table 3: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 4: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 5: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 6: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 7: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 8: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 9: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 10: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 11: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 12: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 13: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 14: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 15: China, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 16: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 17: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 18: India, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 19: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 20: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 21: Japan, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 22: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 23: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 24: Australia, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 25: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 26: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 27: Indonesia, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 28: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 29: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 30: South Korea, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 31: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 32: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 33: Western Europe, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 34: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 35: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 36: UK, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 37: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 38: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 39: Germany, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 40: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 41: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 42: France, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 43: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 44: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 45: Italy, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 46: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 47: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 48: Spain, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 49: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 50: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 51: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 52: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 53: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 54: Russia, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 55: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 56: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 57: North America, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 58: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 59: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 60: USA, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 61: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 62: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 63: Canada, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 64: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 65: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 66: South America, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 67: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 68: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 69: Brazil, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 70: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 71: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 72: Middle East, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 73: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 74: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 75: Africa, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 76: F. Hoffmann-La Roche Ltd Financial Performance

Table 77: Bayer AG Financial Performance

Table 78: Sanofi S.A Financial Performance

Table 79: AstraZeneca PLC Financial Performance

Table 80: Abbott Laboratories Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2018-2023, $ Billion

Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Figure 3: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 4: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 5: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 6: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 7: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 8: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 9: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 10: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 11: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 12: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 13: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 14: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 15: China, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 16: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 17: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 18: India, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 19: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 20: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 21: Japan, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 22: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 23: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 24: Australia, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 25: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 26: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 27: Indonesia, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 28: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 29: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 30: South Korea, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 31: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 32: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 33: Western Europe, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 34: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 35: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 36: UK, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 37: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 38: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 39: Germany, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 40: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 41: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 42: France, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 43: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 44: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 45: Italy, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 46: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 47: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 48: Spain, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 49: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 50: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 51: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 52: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 53: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 54: Russia, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 55: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 56: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 57: North America, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 58: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 59: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 60: USA, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 61: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 62: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 63: Canada, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 64: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 65: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 66: South America, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 67: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 68: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 69: Brazil, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 70: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 71: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 72: Middle East, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 73: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 74: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 75: Africa, Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 76: F. Hoffmann-La Roche Ltd Financial Performance

Figure 77: Bayer AG Financial Performance

Figure 78: Sanofi S.A Financial Performance

Figure 79: AstraZeneca PLC Financial Performance

Figure 80: Abbott Laboratories Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Global Protein Purification And Isolation Market 2022 – Market Opportunities And Strategies

What Is The Pharmaceutical Processing Seals Market Overview In 2022?

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

Rare Neurological Disease Treatment Global Market Report 2024 – By Drug Type (Biologics, Small Molecules), By Therapy (Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies), By Mode Of Administration (Oral, Injectable, Other Modes Of Administration), By Disorders (Aicardi Syndrome, Aicardi-Goutières Syndrome, Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri Syndrome, Creutzfeldt Jakob Disease, Agnosia, Other Disorders), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies And Drug Store, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Neurological Biomarkers Global Market Report 2024 – By Product (Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products), By Application (Alzheimer’s Disease, Parkinson’s Disease, Huntington's Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy), By End-User (Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

HPV Associated Disorders Global Market Report 2024 – By Indication (Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Anal Intraepithelial Neoplasia (AIN), Anal Cancer, Genital Warts, Other Indications), By Therapy (Prevention, Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Bleeding Disorders Treatment Global Market Report 2024 – By Treatment (Desmopressin (DDAVP), Hormone Replacement Therapy, Contraceptives, Anti-Fibrinolytic or Clot-Stabilizing Drugs, Fibrin Sealants, Drugs Applied To Cuts, Pipeline Analysis), By Disease Type (Hemophilia A, Hemophilia B, Von willebrand disease, Liver disease, Other Disease Types), By End User (Hospitals, Clinics, Specialty Clinics, Research Institutes, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Post-Traumatic Stress Disorder Therapeutics Global Market Report 2024 – By Drug Class (Antidepressants, Anti-Anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics Or Second Generation Antipsychotics (SGOs), Beta-Blockers, Other Classes), By Age Group (Pediatric, Geriatric, Adult), By End User (Mental Health Center, Hospitals, Outpatient Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Generic Musculoskeletal Disorders Drugs Global Market Report 2024 – By Treatment Type (Medication, Therapy, Surgery, Other Treatment Types), By Disorder Type (Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types), By Route of Administration (Oral, Parenteral, Other Routes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Headache Disorders Global Market Report 2024 – By Type (Migraine, Tension-Type Headache, Cluster Headache, Medication-Overuse Headache, Other Types), By Treatment (Medication, Heat Therapy, Diet Changes, Acupuncture, Oxygen Therapy), By Diagnosis (Complete Blood Count, Skull X-Rays, Sinus X-Rays, CT Scan, Magnetic Resonance Imaging (MRI)), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Myeloproliferative Disorders Drugs Global Market Report 2024 – By Type (Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), Systemic Masto cytosis (SM)), By Drug Type (JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Other Drug Types), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Retail Stores, Drug Stores) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Frequently Asked Questions

What is the definition of the neurological disorder drugs market?

How will the neurological disorder drugs market drivers and restraints affect the neurological disorder drugs market dynamics? What forces will shape the neurological disorder drugs industry going forward?

The neurological disorder drugs market major growth driver - Rising Neurological Disorders Drive Growth In Drugs Market. For further insights on the neurological disorder drugs market, request a sample here

What is the forecast market size or the forecast market value of the neurological disorder drugs market?

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $79.67 billion in 2023 to $84.60 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure. The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $108.05 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine. For further insights on the neurological disorder drugs market, request a sample here

How is the neurological disorder drugs market segmented?

The neurological disorder drugs market is segmented
1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End UsersFor further insights on the neurological disorder drugs market, request a sample here

Which region has the largest share of the neurological disorder drugs market? What are the other regions covered in the report?

North America was the largest region in the neurological disorder drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the neurological disorder drugs market, request a sample here.

Who are the major players in the neurological disorder drugs market?

What are the key trends in the neurological disorder drugs market?

Major trend in the neurological disorder drugs market - Innovative Approaches In Neurological Disorder Drugs Advancing Treatment For Multiple Sclerosis. For further insights on the neurological disorder drugs market, request a sample here.

What are the major opportunities in the neurological disorder drugs market? What are the strategies for the neurological disorder drugs market?

For detailed insights on the major opportunities and strategies in the neurological disorder drugs market, request a sample here.

How does the neurological disorder drugs market relate to the overall economy and other similar markets?

For detailed insights on neurological disorder drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the neurological disorder drugs industry?

For detailed insights on the mergers and acquisitions in the neurological disorder drugs industry, request a sample here.

What are the key dynamics influencing the neurological disorder drugs market growth? SWOT analysis of the neurological disorder drugs market.

For detailed insights on the key dynamics influencing the neurological disorder drugs market growth and SWOT analysis of the neurological disorder drugs industry, request a sample here.